Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paroxetine + oxycodone
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A drug combination consisting of paroxetine (a selective serotonin reuptake inhibitor antidepressant) and oxycodone (an opioid analgesic). This combination has been studied due to concerns about increased respiratory depression risk. Clinical research has demonstrated that paroxetine combined with oxycodone significantly decreases the ventilatory response to hypercapnia compared to oxycodone alone, which is the primary feedback mechanism protecting against opioid-induced respiratory depression. While paroxetine affects oxycodone metabolism by inhibiting CYP2D6 (reducing conversion to oxymorphone), the respiratory effects appear to be primarily pharmacodynamic rather than pharmacokinetic in nature.
02
Targets
GRK2-DOR interface (GRK2–delta opioid receptor interface)MOR (Mu opioid receptor)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on paroxetine + oxycodone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paroxetine + oxycodone.